Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) Stock Based Compensation: ¥0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603392 Beijing Wantai Biological Pharmacy Enterprise Co Ltd SHSE:603392
54 GF Score
Price ¥30.59
GF Value ¥49.46
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Beijing Wantai Biological Pharmacy Enterprise Co Stock Based Compensation?

Beijing Wantai Biological Pharmacy Enterprise Co SHSE:603392 -0.71% 54 Stock Based Compensation is ¥0 Mil as of Jun. 2026. GuruFocus rates SHSE:603392 with a GF Score™ of 54/100 and a GF Value™ of ¥49.46 (Possible Value Trap). The stock has 2 warning signs investors should review.

Beijing Wantai Biological Pharmacy Enterprise Co's Stock Based Compensation for the three months ended in Jun. 2026 was ¥0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was ¥0 Mil.

Beijing Wantai Biological Pharmacy Enterprise Co Stock Based Compensation Related Terms

Beijing Wantai Biological Pharmacy Enterprise Co Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Beijing Wantai Biological Pharmacy Enterprise Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Wantai Biological Pharmacy Enterprise Co Stock Based Compensation Chart

Beijing Wantai Biological Pharmacy Enterprise Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Beijing Wantai Biological Pharmacy Enterprise Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SHSE:603392
54GF Score
Beijing Wantai Biological Pharmacy Enterprise Co Ltd SHSE:603392
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Wantai Biological Pharmacy Enterprise Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

What does a Stock Based Compensation of ¥0 Mil mean?
Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) has a Stock Based Compensation of ¥0 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Beijing Wantai Biological Pharmacy Enterprise Co and its competitors.
Is Beijing Wantai Biological Pharmacy Enterprise Co's Stock Based Compensation too high?
Beijing Wantai Biological Pharmacy Enterprise Co's current Stock Based Compensation is ¥0 Mil. Overall, Beijing Wantai Biological Pharmacy Enterprise Co has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Beijing Wantai Biological Pharmacy Enterprise Co's Stock Based Compensation compare to VRTX and REGN?
Beijing Wantai Biological Pharmacy Enterprise Co's Stock Based Compensation of ¥0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Beijing Wantai Biological Pharmacy Enterprise Co and its competitors. Beijing Wantai Biological Pharmacy Enterprise Co's current Stock Based Compensation is ¥0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Wantai Biological Pharmacy Enterprise Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) is currently considered Possible Value Trap. The stock's GF Value™ is ¥49.46, compared to a current price of ¥30.59 — trading 38.2% below its estimated fair value. The current Stock Based Compensation is ¥0 Mil. Beijing Wantai Biological Pharmacy Enterprise Co's overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392), the current Stock Based Compensation is ¥0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) Overvalued in 2026?

Based on GuruFocus' analysis, Beijing Wantai Biological Pharmacy Enterprise Co stock appears to be undervalued. The current stock price of ¥30.59 is trading 38.2% below its estimated GF Value™ of ¥49.46. GuruFocus considers Beijing Wantai Biological Pharmacy Enterprise Co to be Possible Value Trap.

Key valuation signals for SHSE:603392:

  • Stock Based Compensation: ¥0 Mil
  • GF Value™: ¥49.46 vs. price of ¥30.59 (38.2% below fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the SHSE:603392 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beijing Wantai Biological Pharmacy Enterprise Co Business Description

Address No. 31, Science Park Road, Changping District, Beijing, CHN, 102206
Beijing Wantai Biological Pharmacy Enterprise Co Ltd is engaged in research, development, production, and sales of in vitro diagnostic reagents, instruments, and vaccines. The company has two segments: Diagnostic and Vaccine. The Diagnostic segment develops and sells in vitro diagnostic reagents such as ELISA, colloidal gold, biochemical, and chemiluminescent kits, along with instruments including chemiluminescent analyzers, fluorescent analyzers, and nucleic acid purification systems. The Vaccine segment focuses on products like the hepatitis E vaccine, the bivalent HPV vaccine, and the nasal spray COVID-19 vaccine. It generates the majority of its revenue from the Diagnostic segment.
54GF Score

Get the complete analysis for SHSE:603392

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥30.59
Price
¥49.46
GF Value